Young-Euy Park

Neurilemmoma of the mandible

Abstract Intraosseous neurilemmoma is rare, representing less than 1% of benign primary bone tumors. The site most commonly involved is the mandible. We report on a neurilemmoma of the mandible in a 30-year-old woman. A panoramic radiograph of the mandible showed a well-defined unilocular osteolytic lesion with a thin uniform sclerotic margin located in the body of the mandible. The CT scan confirmed a well-defined osteolytic lesion with thinning of the cortex of the body of the left side of the mandible. Histologically, the lesion was a moderately cellular neoplasm with distinct palisading and numerous Verocay bodies. Ultrastructurally, the cytoplasmic membranes were distinct and coated by amorphous bands of basal lamina. Complete excision was achieved by removing the tumor from the inferior alveolar nerve.

The impact of osteonectin for differential diagnosis of osteogenic bone tumors: an immunohistochemical and in situ hybridization approach

Abstract Thirty-three osteosarcomas at various grades of histologic differentiation, including chondroblastic, osteoblastic, and fibroblastic variants, were investigated immunohistochemically for evidence of osteonectin. Twenty-two cases of varying types of osteosarcoma were examined with in situ hybridization for mRNA expression of osteonectin. Immunohistochemically, osteonectin was present in all the osteosarcomas in this study. With in situ hybridization, 12 out of 22 osteosarcomas showed a positive signal. Two osteochondrosarcomas, seven chondrosarcomas, and one mesenchymal chondrosarcoma were also studied with regard to the localization of osteonectin, either immunohistochemically or by in situ hybridization. Immunohistochemically, osteonectin was present in all the chondroid lesions except for one osteochondroma. However, in situ hybridization of osteonectin mRNA was negative in all the chondroid lesions we studied. This study revealed that immunohistochemical localization of osteonectin is not useful in providing conclusive diagnosis of osteosarcoma. In situ hybridization of osteonectin mRNA might be useful in differentiating osteosarcoma from nonosteogenic bone tumors.